Ingenol Mebutate 150 mg as Physician-Directed Treatment of Bowen's Disease Under Occlusion.
| Autor: | Alkhalaf A; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Hofbauer GF |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Dermatology (Basel, Switzerland) [Dermatology] 2016; Vol. 232 Suppl 1, pp. 17-9. Date of Electronic Publication: 2016 Aug 11. |
| DOI: | 10.1159/000447391 |
| Abstrakt: | Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis. We report a case with off-label use of IM where Bowen's disease has been successfully treated with physician-directed IM 0.015% gel under occlusion over the chest area. (© 2016 S. Karger AG, Basel.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|